Preclinical evaluation of binimetinib (MEK162) delivered via polymeric nanocarriers in combination with radiation and temozolomide in glioma

BACKGROUND AND PURPOSE: Glioblastoma multiforme (GBM) is the most aggressive subtype of malignant gliomas, with an average survival rate of 15 months after diagnosis. More than 90% of all GBMs have activating mutations in the MAPK/ERK pathway. Recently, we showed the allosteric MEK1/2 inhibitor bini...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:J Neurooncol
Main Authors: Bikhezar, Fatima, de Kruijff, Robin M., van der Meer, Astrid J. G. M., Torrelo Villa, Guzman, van der Pol, Susanne M. A., Becerril Aragon, Gabriel, Gasol Garcia, Ana, Narayan, Ravi S., de Vries, Helga E., Slotman, Ben J., Denkova, Antonia G., Sminia, Peter
Format: Artigo
Jezik:Inglês
Izdano: Springer US 2019
Teme:
Laboratory Investigation
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC6971148/
https://ncbi.nlm.nih.gov/pubmed/31875307
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11060-019-03365-y
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki